AU2005291857A1 - Milk production method - Google Patents

Description

WO 2006/037183 PCT/AU2005/001541 -1 "Milk Production Method" Field of the Invention The present invention relates to a method improving the half-life in milk products. More particularly, it relates to a method for producing milk with an improved shelf 5 life. Background Art Spoilage of milk products may arise from a number of sources. Milk products may spoil as a result of chemical changes caused by a reaction between the products and packaging material or contamination by foreign materials. Fats like butter are 10 subject to rancidity caused by a chemical reaction that breaks down the fatty acids in fat to smaller molecular weight free fatty acids and, at the same time, releases certain odours. Milk products like other foodstuffs are naturally contaminated with micro organisms. To keep numbers of viable micro-organisms as low as possible, 15 processes have been developed to physically remove cells - for example through improved sanitation, heating and temperature control. Refrigeration also increases the time required for milk products to spoil. Another source of spoilage in milk products is the degradation of milk components by enzymes including lipoprotein lipases (LPLs) and metalloproteases. Enzymes 20 are chemicals produced by all living things and bacteria produce enzymes to break down food, allowing the bacteria to access nutrients and proliferate in an environment. Regarding LPLs, rancidity arises from the hydrolysis of milk-fat by these. LPLs can be inactivated, however some bacterial LPLs are heat resistant. Heat 25 resistant LPLs are a major cause of rancidity (Cousin, 1982).

WO 2006/037183 PCT/AU2005/001541 -2 Summary of the Invention In a first aspect of the invention, there is provided a method for improving the half life in milk, processed milk products, concentrates etc. More particularly, there is provided a method for improving the shelf life of milk. 5 According to a first embodiment the inventive method comprises the step of: contacting milk with an antibody raised against a molecule required, for survival and or growth, by at least a micro-organism that is responsible for reducing the half-life of milk or a micro-organism that aids other micro-organisms to reduce the half-life of milk. Desirably the antibody, when contacted with the milk, will form an 10 antibody-antigen interaction with the molecule and will deplete, remove or prevent the molecule from either being a nutrient source for the micro-organism or prevent the activity of the molecule. One such antibody is an antibody generated against lipoprotein lipase from Pseudomonas fluorescens. According to second embodiment the method comprises the step of: inducing the 15 production of at least an antibody in the mammary gland of an animal, which antibody is raised against a molecule required, for survival and or growth, by at least a micro-organism that is responsible for reducing the half-life of milk or a micro-organism that aids other micro-organisms to reduce the half-life of milk. According to a third aspect the invention provides a method for the production of 20 milk containing antibodies which method comprises the steps of: induction of antibodies according to the method detailed above and then collecting and optionally processing the antibody containing milk from the mammal. The collection of milk may be effected using normal milking processes. According to a fourth aspect, the present invention provides a milk product with 25 improved shelf-life, said milk product being prepared according to any one of the above methods and wherein milk produced by the methods is processed into the milk product. The invention also provides a milk product with improved shelf-life, said product being a milk product or derivative whose shelf-life is improved by the WO 2006/037183 PCT/AU2005/001541 -3 addition of an antibody preparation that binds a molecule required, for survival and or growth, by at least a micro-organism that is responsible for reducing the half-life of milk or a micro-organism that aids other micro-organisms to reduce the half-life of milk. 5 Other objects, features, and advantages of the instant invention, in its details as seen from the above, and from the following description of the preferred embodiment. Brief Description of the Drawings Figure 1 shows a photograph of the supramammary gland stained blue due to 10 migration of dye inoculated in the groin area of the animal (photo courtesy of Dr Martin CAKE, Anatomy Department Murdoch University). Figure 2 shows a photograph of the intranasal immunisation of a goat. Figure 3 shows a photograph of the implantation of an antigen releasing device in accordance with an aspect of the present invention into the groin of a sheep. 15 Figure 4 shows the location of the implanted antigen releasing device of Figure 3 in the sheep. Figure 5 shows a schematic diagram of the apparatus used to implant the antigen releasing device. Figure 6 shows a photograph of the diffusion of a lipase protein from an antigen 20 releasing device in accordance with an aspect of the present invention into a milk agar plate. As the enzyme diffuses from the pores of the tube, it hydrolyses the lipids in the milk agar, as evident from the dark zones around the rod. The lipase protein was used as the model antigen for the development of the invention. Figure 7 shows a graph of the level of anti-lipase antibodies in milk from goats 25 immunised with different protocols. The level of anti-lipase antibodies in milk from WO 2006/037183 PCT/AU2005/001541 -4 goats immunised with different protocols. The mean absorbance values of two animals were plotted over 28 days for each protocol. Maximum antibody levels were achieved with the procedure using an antigen releasing device (CRD) and intramuscular injection. 5 Figure 8 shows a graph of the individual absorbance levels of anti-lipase antibodies in two separate animals implanted with an antigen releasing device (ARD) and given intramuscular injections. The levels of anti-lipase antibodies in two separate animals implanted with an antigen releasing device (CRD) and given intramuscular injections. The two results highlight the reproducible nature of the 10 immunisation procedure Figure 9 shows a graph of the level of anti-lipase antibodies in serum from goats immunised with different protocols. The mean absorbance values of two animals were plotted over 28 days for each protocol. Figure 10 shows a comparison of mean anti-lipase anti-body levels in milk (+) and 15 serum (m) produced by immunisation of goats with an antigen releasing device (ARD) and intramuscular injection. Figure 11 shows a graph of anti-lipase antibody production in milk (+) and serum (m) in goats implanted with an antigen releasing devices. The level of anti-lipase antibody levels in milk and the absence of anti-lipase antibodies in serum suggest 20 that the antigens in the antigen releasing device implanted in the groin area are diffusing into the supramammary lymph node. Figure 12 shows a graph of the levels of IgG, IgA and IgM in the milk of inoculated goats. Two groups of animals were inoculated in different locations (Group 1 (Gl) into the flank and Group 2 (G2) in the region adjacent to the 25 supramammary lymph nodes) on Days 0, 10 and 19. The relative levels of IgG, IgA and IgM were determined by ELISA. The levels of all three classes of immunoglobulins were higher in the milk of Group 2 animals when compared to Group 1 animals.

WO 2006/037183 PCT/AU2005/001541 -5 Figure 13 shows photographs of a diffusion assay of milk agar on glass slides illustrating the inhibitory effects of anti-lipase antibodies on the lipolytic activity of the lipase enzyme. Slide 1: PBS or saline was added to the wells. Slide 2: 5mg/mi lipase from P. fluorescens. Slide 3: 5mg/ml of lipase with an antibody 5 negative serum (1:1 dilution). Slide 4: 5mg/ml of lipase with serum that was positive for anti-lipase antibodies (1:1 dilution). Figure 14 shows photographs of a diffusion assay illustrating the inhibitory effects of anti-lipase antibodies on the lipolytic activity of the lipase enzyme on 1% milk in 1% agar. Well 1:1:1 pre-bleed sera + PBS solution. Well 2:1:1 pre-bled sera + 10 lipase solution. Well 3 2.5mg/ml lipase. Well 4 1:1 anti-lipase sera (38 days) + PBS solutions. Well 5:1:1 anti-lipase sera (38 days) + lipase. Well 6: 0.85% PBS. Figure 15 shows photographs comparing the inhibitory activity of anti-lipase antibodies with a non-lipase antibodies. Antibodies to lipase were raised in the 15 serum of two individual animals (X0247 and X0248). These anti-lipase antibody positive serum were compared to non-lipase antibody positive serum from four animals. Well 5 of all six plates contained sera containing the respective antibodies in a 1:1 dilution with the lipase enzyme. Figure 16 shows a graph the pH of milk incubated with lipase and eight dilutions 20 of serum containing anti-lipase antibody, showing that as the concentrations of antibodies decreased the pH changes, suggesting a dose-response to the antibody in the serum. A positive control (lipase only with no serum) and a negative serum (saline or PBS only) were also prepared for comparison. The pH of milk was measured prior to the start of the experiment and one hour after 25 incubation. At the 1:2 and 1:5 dilutions, the pH change was minimal. As the concentrations of antibodies decreased, the pH changes are distinct, suggesting a dose-response to the antibody in the serum.

WO 2006/037183 PCT/AU2005/001541 -6 Figure 17 shows a graph of the pH of milk incubated with serum containing no anti-lipase antibodies. The change in pH over the incubation period (1hr) suggests that lipase is hydrolyzing the lipids in the milk. Figure 18 shows a graph of the pH of milk containing anti-lipase antibodies and 5 different levels of lipase at 370C for 1 hour. For the serum containing high antibody levels, there is no significant change in pH suggesting that the anti-lipase antibody inhibits the hydrolysis of lipids. In contrast, the same comparison with milk with little (or no) anti-lipase antibody shows lipid hydrolysis. Figure 19 shows a graph of the hydrolysis of lipids in milk by lipase (LPL) results 10 in the decrease in pH as free fatty acids are released (+). Serum antibodies to lipase decrease the rate of fatty acid. The rate of decrease in pH is dose dependant. The rate of decrease is greater at the lower concentration (50041) of antibodies (a) when compared to the higher concentration (1000l) of antibodies (A). 15 Figure 20 shows a graph of the dose-dependant inhibition of the hydrolysis of lipids by serum anti-lipase antibodies. Milk was 'spiked' with lipase (LPL). Three different concentrations of anti-lipase antibodies were added and compared to two milk aliquots without any antibody (+: PBS; m: antibody negative serum). The hydrolysis curve as measured by pH change of the lowest antibody concentration 20 (A: 240tl) was similar to the tests with no antibodies, indicating that insufficient antibodies present to inhibit the enzyme. At the higher antibody concentrations (500tl and 1000g1), the shape and rate of hydrolysis is different, as a result of the inhibitory effect of the antibodies. Figure 21 shows a graph of the hydrolysis of lipids in milk in the presence and 25 absence of anti-lipase antibodies. The inhibitory role of anti-lipase on lipase activity was assessed at 100C over 11 days. There is some suggestion that the anti-lipase antibody can inhibit the hydrolysis of fat (+, A). However, there is evidence that other spoilage mechanisms prevail at 10ooC. The rate of pH change WO 2006/037183 PCT/AU2005/001541 -7 is similar regardless; either in the presence of antibodies, in the absence of antibodies or with saline (PBS). Figure 22 shows a graph of the hydrolysis of lipids in milk in the presence and absence of anti-lipase antibodies. Hydrolysis of lipids by lipase in the presence 5 and absence of anti-lipase antibodies was examined by measuring pH change at 40C over a 13 day interval. The pH of the antibody positive test (+) was constant throughout the 13 day trial period. The pH of the anti-body negative test and the saline (PBS) negative control (A and a respectively) started to decrease from about day 6. The shape of the curves differs, suggesting possible difference in 10 the kinetics involved in milk spoilage. Disclosure of the Invention General Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. 15 It is to be understood that the invention includes all such variation and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in the specification, individually or collectively and any and all combinations or any two or more of the steps or features. 20 Each document, reference, patent application or patent cited in this text is expressly incorporated herein by reference, which means that it should be read and considered by the reader as part of this text. That the document, reference, patent application or patent cited in this text is not repeated in this text is merely for reasons of conciseness. 25 The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only.

WO 2006/037183 PCT/AU2005/001541 -8 Functionally equivalent products, compositions and methods are clearly within the scope of the invention as described herein. Through this specification the acronyms CRD and ARD are used interchangeably. Both refer to the antigen releasing device described, disclosed and claimed 5 herein. Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. 10 Other definitions for selected terms used herein may be found within the description of the invention and apply throughout. Unless otherwise defined, all other scientific and technical terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the invention belongs. 15 Detailed Disclosure of the Invention This invention is based on the unexpected discovery that by contacting antibodies against lipoprotein lipase enzymes produced by Pseudomonas species (e.g. Pseudomonas fluorscens) it is possible to produce a milk product with improved properties and shelf-life compared to normal pasteurised milk. 20 Thus, according to a first embodiment the invention provides a method for improving the half-life of milk comprising the step of: a) contacting milk with an antibody raised against at least one of the following: i) a molecule required for survival by at least a micro-organism that is responsible for reducing the half-life of milk; WO 2006/037183 PCT/AU2005/001541 -9 ii) a molecule required for growth by at least a micro-organism that is responsible for reducing the half-life of milk; iii) a molecule required for survival by at least a micro-organism that aids other micro-organisms to reduce the half-life of milk; 5 Preferably, the method also prolongs the shelf-life of the milk. Desirably the antibody, when contacted with the milk, will form an antibody antigen interaction with the molecule and will deplete, remove or prevent the molecule from either being a nutrient source for the micro-organism or prevent the activity of the molecule. One such antibody is an antibody generated against 10 lipoprotein lipase from a species of Pseudomonas such as Pseudomonas fluoroscens The method of the present invention is performed on milk produced by mammals. Preferably, the mammals used to produce the milk are rodents or ruminants. Most preferably, the mammals are goats, sheep or cattle. Desirably the mammals 15 are dairy cattle breeds; however dairy goat or sheep breeds may also be used. The term "milk" used herein refers to both milk and colostrum in the form in which it is produced by the mammal or any derivative of whole milk, such as skimmed milk or whey, in liquid or in solid form. The term "antigen" as used herein refers to any material capable of inducing an 20 antibody response in a treated mammal, wherein the antibody is capable of binding a molecule required, for survival and or growth, by at least a micro organism that is responsible for reducing the half-life of milk or a micro-organism that aids other micro-organisms to reduce the half-life of milk. Antigenic substances that may be employed in the invention including but not limited to: 25 lipoprotein lipases and metalloproteinases from Pseudomonas species fluorescens (such as for example Pseudomonas). Where haptens or peptides are to be used as antigens these should first be conjugated to carrier substances WO 2006/037183 PCT/AU2005/001541 -10 such as proteins using chemistry well known to people versed in the art. (Hanly et al; Review of Polyclonal Antibody Production Procedures, ILAR Journal (1995), 37:3, 93-118). Antibody molecules that may be used in the method of the invention include intact 5 immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contain the paratope. Such paratope containing portions include those portions known in the art as Fab, Fab', F(ab') 2 and F(v). Fab and F(ab') 2 . These portions of antibodies may be prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially 10 intact antibodies by methods that are well known. See for example, U.S. Pat. No. 4,342,566. Fab' antibody portions are also well known and are produced from F(ab') 2 portions followed by reduction of the disulfide bonds linking the two heavy reduction of the disulfide bonds linking the two heavy chain portions as with mercaptoethanol, and followed by alkylation of the resulting protein mercaptan 15 with a reagent such as iodoacetamide. An antibody containing intact antibody molecules are preferred, and are utilised as illustrated herein. In a second aspect of the invention, there is provided a method for improving the half-life of milk comprising the step of: a) inducing the production of at least an antibody in the mammary gland of an 20 animal, which antibody is raised against at least one of the following: i) a molecule required for survival by at least a micro-organism that is responsible for reducing the half-life of milk; ii) a molecule required for growth by at least a micro-organism that is responsible for reducing the half-life of milk; 25 iii) a molecule required for survival by at least a micro-organism that aids other micro-organisms to reduce the half-life of milk; WO 2006/037183 PCT/AU2005/001541 -11 iv) a molecule required for growth by at least a micro-organism that aids other micro-organisms to reduce the half-life of milk. Preferably, the method also prolongs the shelf-life of the milk. Methods for the induction of antibody production in milk will include the step of: 5 implanting at least one antigen releasing device adjacent to or within at least one supramammary lymph node, wherein in use the antigen releasing device releases an antigen into the tissue area around the supramammary lymph node which stimulates antibody secretion into a mammary gland. According to this aspect of the invention the distance of the implant from the 10 supramammary gland should be at least close enough that the release of antigen from the antigen releasing device causes the antibody response of the mammal (into which it is implanted) to be maintained at a level facilitates the production of antibodies in milk at levels that are therapeutically or anti-microbially suitable. For example, the ARD may be implanted in the udder. Alternatively by way of 15 illustration the antigen releasing device is preferably implanted at a distance of up to 150 mm from at least one supramammary lymph node, wherein in use the antigen releasing device releases an antigen into the tissue area around the supramammary lymph node which stimulates antibody secretion into a mammary gland. Preferably, the antigen releasing device is implanted either adjacent to or 20 at a distance of between about 1 mm and 100 mm from the supramammary lymph node. Most preferably, the distance is between about 50 mm and 100 mm. Implantation of the antigen releasing device adjacent to or within at least one supramammary lymph node causes the antigen contained in the antigen releasing device to be released into the tissue near and within the node (Figure 1). This in 25 turn stimulates the node to generate antibodies to the antigen. These antibodies are secreted into the mammary glands and therefore enter the milk of the mammal.

WO 2006/037183 PCT/AU2005/001541 -12 The size, characteristics and choice of antigen releasing device is dependant on the size and properties of the antigen of interest. It is desirable that the choice of antigen releasing device allows the antigen contained therein to be released from the device at a rate which causes the antibody response of the mammal into 5 which it is implanted to be maintained at a desirable level. Devices for slow release of compositions are described in, for example, US Patent No. 3,279,996, whilst immunopotentiating devices for the sustained release of antigen are described, for example, in Australian Patent No. 740133 A porous silicon implant impregnated with a beneficial substance is described in 10 Patent No. DE69917625D. An implantable device for molecule delivery is described in U.S Patent No. 6,716,208. Other suitable examples of sustained release preparations include semipermeable matrices of solid hydrophobic polymers containing the protein, which matrices are in the form of shaped articles, e.g., films, or microcapsules compressed into delivery devices. Examples of 15 sustained-release matrices include polyesters, hydrogels [e.g., poly(2 hydroxyethyl-methacrylate) as described by Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981) and Langer, Chem. Tech. 12:98-105 (1982) or poly(vinylalcohol)], polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al., Biopolymers 20 22:547-556 [1983]), non-degradable ethylene-vinyl acetate (Langer et al., supra), degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOTTM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Another reference is B.Baras, M.A. Benoit & J.Gillard (2000) "Parameters influencing the 25 antigen release from spray dried poly (DL-lactide) microparticles." International Journal of Pharmaceutics, 200:133-145. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antigens remain in the body for a long 30 time, they may denature or aggregate as a result of exposure to moisture at 370C, resulting in a loss of biological activity and possible changes in immunogenicity.

WO 2006/037183 PCT/AU2005/001541 -13 Rational strategies can be devised for antibody stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular SS or disulfide bond formation through thio-disulfide interchange, stabilisation may be achieved by modifying sulfhydryl residues, 5 lyophilising from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions. Sustained-release fragment compositions also include liposomally entrapped fragments. Liposomes containing the antibody are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692 10 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese patent application 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily the liposomes are of the small (about 200-800 Angstroms) unilamellar type. Other devices for the slow release of antigen into the tissue near the 15 supramammary lymph node are encompassed within the present invention. An effective amount of antigen to be employed therapeutically will depend, for example, upon the objectives, the route of administration, the type of antigen and/or adjuvant and the condition of the mammal. Accordingly, it will be necessary for the therapist to titre the dosage and modify the mode of 20 administration as required to obtain the optimal effect. Typically, the operator will administer an antigen until a dosage is reached that achieves the desired effect. The progress of this therapy is easily monitored by conventional assays. In the further aspect of the invention, there is provided a method for inducing the sustained release of antibodies in milk comprising the further step of administering 25 a primer composition by an administration route selected from intramammary, intraperitoneal, intramuscular or intranasal. Administration of a primer may take place before, during or after implanting the antigen releasing device. It is preferable that the primer composition be delivered to a mucosal surface so that antibody production on mucosal surfaces (of which the mammary gland is one) is 30 preferentially stimulated.

WO 2006/037183 PCT/AU2005/001541 -14 The primer composition administration could be a single administration, or could comprise a number of administrations at intervals over a period of days or weeks. Timing of the administration of primer composition is generally spaced based on contemporary immunisation protocols (for example, every 2 weeks). To avoid 5 local irritation and congestion, it is usually preferred that the primer composition not be administered to the same site more frequently than every second week. The initial exposure of this priming step stimulates the low level production of antibodies, which production is then increased and maintained by antigen released by the antigen releasing device. 10 The method of the present invention may also comprise the additional step of administering a booster composition comprising antigen to a mammal by an administration route selected from intramammary, intraperitoneal, intramuscular and/or intranasal after the antigen releasing device has been implanted. It is preferable that the booster composition be delivered to a mucosal surface so that 15 antibody production on mucosal surfaces (of which the mammary gland is one) is preferentially stimulated. Such booster compositions could be administered as a single administration, or could comprise a number of administrations at intervals over a period of days or weeks. Administration of booster compositions is generally spaced to suit the 20 convenience of the operator. To avoid local irritation and congestion, it is usually preferred that administration of the booster composition to the same site not be more frequent than every other week. In a preferred method, the antigen administered is the same for each step of the method. Therefore, the same antigen may be used in the antigen releasing 25 device, the primer composition and/or the booster composition. The use of adjuvants both within the antigen releasing device and in the compositions used for priming and boosting is also desirable. An adjuvant can serve as a tissue depot that slowly releases the immunogen and also as a lymphoid system activator that non-specifically enhances the immune response [Hood et al., WO 2006/037183 PCT/AU2005/001541 -15 in Immunology, p. 384, Second Ed., Benjamin/Cummings, Menlo Park, California (1984)]. Suitable adjuvants for use with the antigens of the invention include but are not limited to the following: Freund's complete adjuvant (FCA), Freund's incomplete adjuvant (FIC), TiterMax Gold T M , adjuvant 65, cholera toxin B subunit, 5 IL1-B Fragment 163-171 synthetic human adjuvant, alhydrogel; or bordetella pertussis, muramyl dipeptide, cytokines, saponin, Adju-Phos, Algal Glucau, Algammuliu, Alhydrogel, Antigen Formulation, Avridine, Bay R1005, calcitrial, calcium phosphate, Gel, CRL 1005, cholera Holotoxin (CT), DDA, DHEA, DMPC, DMPG, DOC/Alum Complex, Gamma Inulin, Gerbu Adjuvant, GMDP, Imiquimod, 10 Imuither, Interferon-gamma, ISCOM(s), Iscoprop 7.0.3, Loxoribine, LT-OA or LT Oral adjuvant, MF59, MONTANIDE ISA51 and ISA720, MPL, MTP-PE, MTP PE Liposomas, murametide, murapalmitive, NAGO, Nonionic surfactant vesides, Pleuram, PLGA, PGA and PLA, Pluronic L121, PMMA, PODDS, Poly Ra, Polyru Polyphophazene, Polysorbate 80, Protein Cochleates, QS-21, Quil A, Rehydrogel 15 HPA, Rehydrogel LV, S-28465, SAF-1, Sclavo, peptide, Seudai Protediposomes, sendai-contaiming lipid matrices, Span 85, specal, squalene, stearyl Tyrosine, Theramide, Threonyl-MDP, Ty Particles, saponin Q521, MF59, Alum.. In relation to the step of administering the priming composition or the boosting composition, preferably the antigenic substances are suspended in liquid medium 20 for infusion or injection according to known protocols. Any appropriate carriers, diluents, buffers, and adjuvants known in the art may be used. Suitable suspension liquids include saline solution, water, and physiologic buffers. If administration of the priming composition or the boosting composition is by injection, preferably prior to injection the antigens are emulsified in appropriate 25 carriers with adjuvant using, for example, a laboratory homogeniser. In one example of such a method, aqueous antigen is mixed with 3 volumes of adjuvant and emulsified until a stable water-in-oil emulsion is formed. The presence of a stable emulsion can be demonstrated using tests well known in the art. In a further aspect of the invention, the method further comprises a preselection 30 step. In this step individual animals are tested and selected for their ability to WO 2006/037183 PCT/AU2005/001541 - 16 produce antibodies. Considerable between-animal variability exists for the production of antibodies. This preselection step, wherein the animals showing the best antibody titre responses are selected, assists in decreasing the between animal variability factor. This process may similarly be used to build groups of 5 animals particularly suited to antibody production. According to a third aspect the invention provides a method for the production of milk with a prolonged half-life containing antibodies, which method comprises the steps of: induction of antibodies according to the method detailed above and then collecting and optionally processing the antibody containing milk from the 10 mammal. The collection of milk may be effected using normal milking processes. Preferably, the method also prolongs the shelf-life of the milk. According to a fourth aspect, the present invention provides a milk product with improved half-life, said milk product being prepared from milk generated according to any one of the above methods and wherein milk produced by the 15 methods is processed into the milk product. The invention also provides a milk product with improved half-life, said product being a milk product or derivative whose half-life is improved by the addition of an antibody raised against at least one of the following: i) a molecule required for survival by at least a micro-organism that is 20 responsible for reducing the half-life of milk; ii) a molecule required for growth by at least a micro-organism that is responsible for reducing the half-life of milk; iii) a molecule required for survival by at least a micro-organism that aids other micro-organisms to reduce the half-life of milk; 25 iv) a molecule required for growth by at least a micro-organism that aids other micro-organisms to reduce the half-life of milk.

WO 2006/037183 PCT/AU2005/001541 -17 This milk is useful in the form obtained directly from the mammal but may be processed if required. Examples of processing steps include heat treatment, ultra violet radiation, concentration, supplementation with food additives, drying into concentrates, milk powders and the like. 5 The present invention also provides a milk product with prolonged shelf-life, said product being a milk product or derivative whose shelf-life is prolonged by the addition of an antibody raised against at least one of the following: i) a molecule required for survival by at least a micro-organism that is responsible for reducing the shelf-life of milk; 10 ii) a molecule required for growth by at least a micro-organism that is responsible for reducing the shelf-life of milk; iii) a molecule required for survival by at least a micro-organism that aids other micro-organisms to reduce the shelf-life of milk; iv) a molecule required for growth by at least a micro-organism that aids other 15 micro-organisms to reduce the shelf-life of milk. Milk and milk products in which the method of the invention may have benefit may include foodstuffs, drinks (e.g., energy or sports drinks) and animal feeds. For example, the milk may possibly be used as an ingredient in, baby food, bakery products (for example, a bread, yeasted good or cake) or bakery supply products 20 (for example, custard or bakery fillings or toppings), batter or breading, cereal, confectionary, flavour or beverage emulsions, fruit fillings, gravy, soups, sauces (eg meat sauces) or food thickeners, UHT treated gravy, meal components (e.g., vegetarian meal/components), meat products (e.g., comminuted meat products, sausages, burgers, grill steaks, canned meats, meat pies, fish preparations, meat 25 patties, meat spread and pastes), pizza toppings, pet foods, pharmaceuticals or neutraceuticals, potato products, dressings (e.g., salad or low fat dressings), snack or cracker spreads (e.g., savoury or sweet spreads), pasta products (e.g.

WO 2006/037183 PCT/AU2005/001541 -18 noodles), fat-filled powders, quiches or flans, cheese or cream mimetics and other substitute dairy products not specifically detailed within this description of invention (e.g. desserts, flavoured milk drinks, milk shakes, cheeses, cheese spreads or dips). 5 Examples Further features of the present invention are more fully described in the following non-limiting Examples. It is to be understood, however, that this detailed description is included solely for the purposes of exemplifying the present invention. It should not be understood in any way as a restriction on the broad 10 description of the invention as set out above. Example 1 Preparation of Antigen Releasing Device Minus Adjuvant MATERIALS 15 (i) 0.15g mannitol-D (Sigma-Aldrich) (ii) 0.15g sodium citrate (Proanalys) (iii) 11.25mg lipase from Pseudomonas fluorescens (Sigma-Aldrich) (iv) 0.75 ml part A Silastic (Dow Corning Q7-4850) (v) 0.75 ml part B Silastic (Dow Corning Q7-4850) 20 (vi) 2 x 2.5 ml disposable syringes (Terumo) (vii) 2 x 1 ml syringe (Terumo) (viii) 2 x 12G x 4 inch stainless steel hypodermic needles (ix) 37 oC incubator (x) sterile petri dish 25 (xi) sterile scalpel (xii) sterile spachella (xiii) 32ml glass McCartney bottle WO 2006/037183 PCT/AU2005/001541 - 19 METHODS (i) Remove pistons from all syringes (ii) Part A - silastic placed into 1 ml syringe using spatula. Piston replaced into 5 syringe and 0.75ml quantity dispensed into one 2.5ml syringe. (iii) Procedure repeated for Part B. (iv) Lipase, mannitol and sodium citrate are combined and mixed in a small glass McCartney then placed into the 2.5ml syringe containing Part A of the silastic. Part B was then expelled from its syringe into the other 2.5ml syringe 10 effectively 'sandwiching' the lipase, mannitol and sodium citrate between Part A and Part B of the silastic in one syringe. The piston was replaced in this syringe and removed from the empty syringe. The contents of the first syringe were expelled into the second syringe then its piston replaced. The procedure was repeated 20 times to effectively mix all reagents. The reagents were finally 15 expelled into two 12G needles and stored at 370C for three days. The cured silastic was extracted from the needles, cut into 3cm lengths in the open petri dish and placed under UV light for 24 hours before being stored in sterile 10ml centrifuge tubes at -200C. Each 3cm ARD contained 1 mg lipase, 13mg mannitol, 13mg sodium citrate, in 250pl of total silastic. 20 Example 2 Preparation of Antigen Releasing Device including adjuvant MATERIALS 25 (i) 0.3g mannitol-D (Sigma-Aldrich) (ii) 0.3g sodium citrate (Proanalys) (iii) 22.50mg lipase from Pseudomonas fluorescens (Sigma-Aldrich) (iv) 1.2mg IL1-B Fragment 163-171 synthetic human (Sigma) (v) 1.5 ml Part A Silastic (Dow Corning Q7-4850) 30 (vi) 1.5 ml Part B Silastic (Dow Corning Q7-4850) (vii) 2 x 2.5 ml disposable syringes (Terumo) (viii) 2 x 1 ml syringe (Terumo) WO 2006/037183 PCT/AU2005/001541 - 20 (ix) 2 x 12G x 4 inch stainless steel hypodermic needles (x) 37 oC incubator (xi) sterile petri dish (xii) sterile scalpel 5 (xiii) sterile spachella (xiv) 32ml glass McCartney bottle METHODS (i) Remove pistons from all syringes 10 (ii) Part A silastic placed into 1 ml syringe using spatula. Piston replaced into syringe and 0.75ml quantity dispensed into one 2.5ml syringe. (iii) Procedure repeated for Part B. (iv) Lipase, mannitol and sodium citrate mixed in a small glass McCartney then placed into the 2.5ml syringe containing Part A of the silastic. Part B was then 15 expelled from its syringe into the other 2.5ml syringe effectively 'sandwiching' the lipase, mannitol and sodium citrate between Part A and Part B of the silastic in one syringe. The piston was replaced in this syringe and removed from the empty syringe. The contents of the first syringe was expelled into the second syringe then its piston replaced. The procedure was repeated 20 times to effectively mix 20 all reagents. The reagents were finally expelled into two 12G needles and stored at 37 oC for three days. The cured silastic was extracted from the needles, cut into 3cm lengths in the open petri dish and placed under UV light for 24 hours before being stored in sterile 10ml centrifuge tubes at -20 oC. Each 3cm ARD contained 1mg lipase, 13mg mannitol, 13mg sodium citrate, 50pg ILl-B, in 250Pl 25 of total silastic. Example 3 Delivery of ARD A device was purpose designed and built comprising a 10ml disposable luer lock 30 syringe, a 10G x 4 inch stainless steel hypodermic needle and a 90mm x 10G stainless steel welding rod (see Figure 5). The device was assembled with the rod attached to the piston of the syringe and passing through the needle. The WO 2006/037183 PCT/AU2005/001541 - 21 piston was withdrawn about 3cm allowing for free space near the tip of the needle in which to insert the antigen releasing device. Thus, when the piston is depressed, the antigen releasing device is expelled from the needle by the rod (see Figure 5). 5 The animal was placed on the floor on its back and restrained by animal handlers. An area approximately 3cm x 10cm right lateral and adjacent to the udder was swabbed with iodine. 2ml of 2% lignocaine infiltrated the cutaneous tissue through a 26G hypodermic needle as a local anaesthetic. The 10 OG needle 10 housing the ARD was inserted in the posterior end of this area and pushed to the anterior end subcutaneously. The piston was depressed and needle withdrawn simultaneously. The point of insertion was swabbed with iodine. In most cases the antigen releasing device could be felt in situ. Example 4 15 Preparation of Lipase nasal inoculum MATERIALS (i) 15.5 mg lipase from P.fluorescens (Sigma-Aldrich) (ii) 38.75ml 0.85% saline (Excel laboratories) 20 (iii) 1 mg Cholera Toxin B Subunit (US Biological) (iv) 2.5ml syringes (v) 50ml sterile tube (Falcon) (vi) 8-10cm length of approximately 20G plastic tube (e.g. from winged infusion set (Terumo)) 25 METHODS (i) All reagents were combined in 50ml tube on day of first administration. (ii) The remainder was stored at 40C until used.

WO 2006/037183 PCT/AU2005/001541 - 22 Example 5 Delivery of Nasal Inoculum 2.5ml of inoculum (containing 1mg lipase, 64.5pg Cholera Toxin B Subunit) was 5 drawn into syringe with the 20G tube from the infusion set attached. 60-80% of tube length was placed into right nostril of animal and slowly dispensed whilst simultaneously withdrawing the tube from the nostril (Figure 2). Example 6 Preparation of Lipase Intramuscular injected inoculum 10 MATERIALS (i) 36.5mg of lipase from P.fluorescens (Sigma) (ii) 9.1 ml of 0.85% saline (Excel Laboratories) (iii) TiterMax GoldTM adjuvant 15 (iv) glass McCartney bottle (v) 3ml all plastic syringes (Teruma) (vi) stainless steel double-hub (vii) 23G x 1 inch hypodermic needle 20 METHODS (i) Lipase and saline were combined in glass McCartney giving a concentration of 4mg/mi on the day of first administration. The remainder was stored at 4 oC until required. Example 7 25 Delivery of Intramuscular Inoculum 0.5ml of 4mg/mi lipase in saline solution as drawn into syringe and emulsified with 0.5ml TiterMax GoldTM as per manufacturers instructions. Inoculum was administered intramuscularly (IM) in the rear of the left hind leg using 23G x 1 inch WO 2006/037183 PCT/AU2005/001541 - 23 needle attached to the syringe. Animals received IM injections Day 7, Day 14 and Day 21. Example 8 Immunisation Protocol 1 5 The animals were given an IM injection in the flank, the commonly used route for immunisation. Two animals were immunised by the intramuscular route (IM) with lipase from Pseudomonas fluorescens on day 0 with 1250 pg lipase emulsified with 750 ul titremax. The animals received a primary boost (950ug lipase and 560 ul titremax) 10 and a secondary boost (2500ug lipase and 500 pl titremax) on day 12 and day 24 respectively. Animals were bled on the days of immunisation and blood samples were collected at monthly intervals after the immunisation program. Example 9 Immunization Protocol 2 15 The animals were given antigen inoculation by antigen releasing device and/or injection. Table 1 summarises the schedule of inoculums and refers to 6 animals and one antigen. Table 1: Protocols for initial trial of antigen releasing device (ARD).

WO 2006/037183 PCT/AU2005/001541 - 24 Trial CRD and S/C injection of Ag to assess Ab secretion via mammary Date Tag Ag Amount Adjuvant Amount Delivery Total Vol Location Milk y/n Bleed y/n 28/04/2004 White 651 8RS Lipase 2.5 mg T/Max 500ul S/C iml groin Y Y 28/04/2004 Black 1292 BX8 Lipase 2.5 mg T/Max 500ul S/C 1m l groin Y Y 28/04/2004 Black 1675 BX8 Lipase 250ug unsheathed silastic CRD S/C RH groin Y Y 28/04/2004 White 552 8RS Lipase 250ug sheathed silastic CRD IS/C RH groin Y Y Date Tag Ag Amount Adjuvant Amount Delivery Total Vol Location Milk y/n Bleed y/n 13/05/2004 White 651 8RS iUpase 0 0 0 0 0 0 Y Y 13/05/2004 Black 1292 BX8 Lipase 0 0 0 0 0 0 Y Y 13/05/2004 Black 1675 BX8 Lipase CRD Y Y 13/05/2004 White 552 8RS Lipase CRD Y Y 13/05/2004 White 367 lipase 1img / 12mg mannitol/12mg SC-CRD 30x2mm Rh groin Y Y 13/05/2004 Orange468 lipase img / 12mg mannitol/12mg SC-CRD 30x2mm Rh groin Y Y Date Tag Ag Amount Adjuvant Amount Delivery Total Vol Location Milk y/n Bleed y/n 28/05/2004 White 651 8RS Lipase 2.5 mg T/Max 500ul S/C im I RH rump Y Y 28/05/2004 Black 1292 BX8 Lipase 0 0 0 0 0 0 Y Y 28/05/2004 Black 1675 BX8 Lipase 0 0 0 0 0 0 Y Y 28/05/2004 White 552 8RS Lipase 2.5 mg T/Max 500ul S/C imi RH rump Y Y 28/05/2004 White 367 lipase 2.5 mg in 2.5 ml saline 2.5ml nasal Y Y 28/05/2004 Orange 468 lipase 2.5mg T/Max 500ul S/C Ilml Lhrump Y Y Date Tag Ag Milk y/n I Bleed y/n 1/07/2004 White 367 lipase Y Y 1/07/2004 Orange 468 lipase I Y Y Example 10 Immunisation protocol 3 Protocols used 2 animals per group with 12 goats used in total. Six different 5 protocols were evaluated in two separate animals to determine an optimal procedure to produce sustained antibody levels in milk, summarised in Table 4 and 5. Table 4: The immunisation protocols used to stimulate the production of antibodies in milk. 10 WO 2006/037183 PCT/AU2005/001541 - 25 Innoculatio Protocol Sampling Frequency Milk Blood Group Description Adjuvant Day 1 Day 7 Day 14 Day 21 Collection Collection 1 Intramuscular (IM) YES IM injection IM boost IM injection Daily 3-4 day injection only intervals 3-4 day 2 ARD only YES Implant ARD Daily intervals 3 Intranasal (IN) spray YES IN innoculati IN boost IN boost Daily 3-4 day only intervals 4 Intramuscular (IM) YES Implant ARD Daily 3-4 day injection + ARD YES Implant ARD intervals 5 Intranasl (IN) spriay + YES IM injection IM boost IM injection Daily 3-4 day S ARD intervals 3-4 day 6 ARD only NO Implant ARD Daily intervals WO 2006/037183 PCT/AU2005/001541 - 26 Table 5: The immunisation protocols used to stimulate the production of antibodies in milk. Group 1- inject S/Mark Inoculum Amount Delivery Site Freq lipase 2.0mg L.M R/h quart Day 7 TiterMax 500ul Day 14 saline 500ul Day21 Group 2 - CRD inc Adj . S/Mark Inoculum Amount Delivery Site Freq lipase img CRD RH groin Day 0 mannitol 13mg sod citrate 13mg IL-1B 50ug silastic 250ul _ _ :', ... Group 3 nasat only S/Mark Inoculum Amount Delivery Site Freq lipase 1mg nasal nostril Day 7 C/Tox Day 14 saline 2.5ml Day 21 Group CRD & inj S/Mark Inoculum Amount Delivery Site Freq lipase img CRD RH groin Day 0 mannitol 13mg sod citrate 13mg IL-1B 50ug silastic 250ul i I.......NO....I I lipase 2.0mg I.M R/h quart Day 7 TiterMax 500ul Day 14 saline 500ul Day 21 Group 5 - CRD & nasal S/Mark Inoculum Amount Delivery Site Freq lipase 1mg CRD RH groin Day 0 mannitol 13mg sod citrate 13mg IL-1B 50ug silastic 250ul lipase 1mg nasal nostril Day 7 C/ Tox Day 14 saline 2.5m[ Day 21 Group 6 - CRDminusAdj S/Mark Inoculum Amount Delivery Site Freq lipase 1mg CRD RH groin Day 0 mannitol 13mg sod citrate 13mg silastic 250ul 5 WO 2006/037183 PCT/AU2005/001541 - 27 A total of 12 goats were studied, with two goats dedicated to each inoculation regime. The presence of anti-lipase antibodies was evaluated with Enzyme Linked Immunosorbent Assay (ELISA). The mean absorbance value less that of the blank control of the daily milk samples were plotted (Figure 6). Results were 5 reproducible between animals, as shown in Figure 7. All six regimens were successful in raising antibodies. However, the relative concentrations of antibodies for each group varied. The highest mean absorbance value; which is indicative of the greatest concentration of antibodies produced; was recorded for the Group 4 animals. The Group 4 animals received 10 an ARD implant on Day 0 of the program and 3 subsequent injections to the back flank area on Days 7, 14 and 21. The mean absorbance value of Group 4 was greater than the value produced by the Group 1 goats, who only received IM injections at day 7, 14 and 21. Both Group 1 and 4 animals showed some response up to approximately Day 14. 15 At Day 15, the levels of anti-lipase antibodies increased substantially, presumably a consequence of the secondary immune response. The higher levels of antibodies were sustained for the duration of the study, in this case up to Day 28. The levels of anti-lipase antibodies in the serum of the inoculated animals was also measured, as shown in Figures 8, 9, 10 and 11. Figure 8 shows results of 20 the individual absorbance levels of anti-lipase antibodies in two separate animals implanted with an antigen releasing device (ARD) and given intramuscular injections. Figure 9 shows results of the level of anti-lipase antibodies in serum from goats immunised with different protocols. Figure 10 shows results of a comparison of mean anti-lipase anti-body levels in milk and serum produced by 25 immunisation of goats with an antigen releasing device (ARD) and intramuscular injection. Figure 11 shows the anti-lipase antibody production in milk and serum in goats implanted with an antigen releasing device. The level of anti-lipase antibody levels in milk and the absence of anti-lipase antibodies in serum suggest WO 2006/037183 PCT/AU2005/001541 - 28 that the antigens in the antigen releasing device implanted in the groin area are diffusing into the supramammary lymph node. Example 11 Immunization Protocol 4 5 The protocol used two lactating goats (Capra hircus) for each group, with four goats used in total. The antigen used was lipase from Pseudomonas fluorescens. SPreparation for immunisation protocol 1. Emulsify 30mg of lipase in 15ml 0.85% saline. 2. Emulsification with Titermax Gold was according to manufacturer's 10 specification. The lipase in saline solution was mixed with an equal volume of Titremax Gold (1:1). 3. Dispense iml into 2.5ml syringe for administration (each 1ml dose contains 1 mg lipase) 4. Two groups of animals were inoculated on Day 0, 10 and 19. 15 5. Group 1 was inoculated in the left flank and Group 2 was inoculated adjacent to the supramammary lymph node. 6. Milk and serum was collected. * Coating plates for Enzyme Linked Immunosorbent Assay (ELISA) 1. Prepare 2.5Rg/ml of antigen in coating buffer. 20 2. 1001l of the mixture was dispensed into each well of a 96 well ELISA tray. 3. The plates were covered and were left to stand overnight at 40C. * Enzyme Linked Immunosorbent Assay (ELISA) protocol 1. Prior to use, the coated plates were washed 3 times with PBS Tween. 2. A serum diluent of 1% Human serum in PBS Tween. 25 3. Load 100pl of the serum diluent into each well. 4. Load 1 R1 of sample of interest to well. 5. Plates were incubated at 370C for 2 hours.

WO 2006/037183 PCT/AU2005/001541 - 29 6. Plates were washed 3 times with PBS Tween. 7. 1/1000 dilutions of mouse a-sheep IgG, mouse ac-sheep IgA and mouse a sheep IgM in 1% serum diluent (1% Human serum in PBS Tween) were prepared. 5 8. Load 100pl into respective wells. 9. The plates were placed in 370C for 2hrs. 10.The plates were washed 3 times with PBS Tween. 11.1/2500 dilution of rabbit a-mouse IgG (H+L) in 1% serum diluent was prepared. 10 12. Load 100pl per well. 13. Incubate at 370C for 2hrs. 14.The plates were washed 3 times with PBS Tween. 15.A 1/100 dilution of 250mg/ml Nitrophenyl phosphate in Diethanolamine Buffer was prepared. 15 16. Load 100l per well. 17. Incubate at room temperature for approximately 20 to 30 minutes. 18.The reaction was terminated with 50ul of 3.75M NaOH. 19. ELISA plates were read at 405nm. * Results 20 Milk collected was analysed by ELISA for levels of IgG, IgA and IgM. Results from Group 1 (intermuscular into the flank - designated Gl) and Group 2 (stimulation of the supramammary lymph node - G2 animals) in Figure 13 shows higher levels of all three classes of immunoglobulin produced in the milk of Group Example 12 25 Collection and storage of milk samples MATERIALS (i) Beckman Acuspin refrigerated centrifuge (ii) Rennet Type II from Mucor meihei (Sigma) in Hp water at a concentration 30 of 2mg/ml WO 2006/037183 PCT/AU2005/001541 - 30 (ii) 10ml sterile centrifuge tubes (iv) P1000 pipetteman (v) 1 ml disposable transfer pipettes (vi) Smi plastic storage tubes 5 (vii) 370C incubator METHOD Milk was collected by hand milking into 32ml glass McCartney bottles in the absence of any chemical or mechanical stimuli. Milk was generally collected in 10 the morning without prior separation from kids. Samples were stored on ice after collection and transferred as soon as practicable thereafter. Milk was transferred to sterile 10mi centrifuge tubes and centrifuged at 2000rpm for 15mins at 40C. Milk was aspirated from under the solid fat layer using disposable pipette and placed in fresh 1 Oml tube. The pipette was carefully plunged through the fat layer 15 into the milk layer below. 2mg/ml Rennet solution was added to the milk at the ratio of 0.4ml rennet to 5ml milk, tubes were shaken then incubated at 37 0 C for 1 to 2 hours. Tubes were centrifuged at 5000rpm x 15mins at 4 0 C. Supernatant was removed by transfer pipette and stored at -200C. Antibodies in the milk were quantified by the ELISA. 20 Example 13 Collection and storage of blood samples MATERIALS (i) 7ml of 9ml VacutainersTM (Bectco Dickinson) for serum collection 25 (ii) 20G x 1.5inch VacutainerTM (Bectco Dickinson) needles and holder METHOD Blood samples were taken from the jugular vein using VacutainerTM collection tubes, holder and needle. Tubes were stored at 4 0 C. Samples were centrifuged WO 2006/037183 PCT/AU2005/001541 -31 at 4000rpm x 15min at 40C. Upper serum layer was removed using a transfer pipette and stored at -20 oC. Example 14 Enzyme-Linked Immunosorbent Assay 5 MATERIALS (i) 10 x Phosphate Buffer Saline (PBS); 1L double distilled water, 1.91g

KH

2

PO

4 (BDH Chemicals Aust Pty Ltd), 6.1g Na 2

HPO

4 (ASAX Chemicals), 2g KCI (BDH Chemicals Aust Pty Ltd), 10 (ii) 80g NaCI, 1.95g NaN 3 (Sigma Aldrich), pH to 7.4 (iii) 200ml Carbonate coating buffer pH 9.6 containing; 200ml double distilled water, 3.18g Na 2

CO

3 (BDH), 5.88g NaHCO 3 (BDH), 0.39g NaN 3 (Sigma). (iv) 0.85% saline (Excel Laboratories) (v) 0.25 mg/ml lipase from P.fluorescens (Sigma Aldrich) in carbonate coating 15 buffer (vi) PBS-TW20 plate washing solution (BDH); 200ml 10 x PBS (as above), 1800mi distilled water, 1 ml Tween-20 (Labchem) (vii) Serum diluent; 200ml glycerol (BDH), 29g NaCI (BDH), 0.2g KH 2

PO

4 (BDH), 0.61g Na 2

HPO

4 (BDH), 0.2g KCI (BDH), 1.95g NaN 3 (Sigma), 20 distilled water to 1L, 1.5ml Tween-20 (Labchem), pH to 7.4. Store 4 0 C. Dessicated BSA (CSL) added to desired aliquot at 1% concentration, prior to use. (viii) Saline 0.85% (Excel Laboratories) (ix) Donkey anti-goat IgG-Horse Radish Peroxidase (HRP) (Promega) 25 (x) 1 M H 2 SO4 (AJAX Finechem) (xi) TMBS EIA solution (BioRad) Parts A & B (xii) P200 pipetteman and tips (xiii) P20 pipetteman and tips (xiv) NuncTM polsorb 96 well ELISA plates 30 (xv) BioRadTM 96 well plate spectrophotometer model 450 WO 2006/037183 PCT/AU2005/001541 - 32 METHOD 100 l of lipase in carbonate buffer was added to the wells of the ELISA plate and stored at 40C overnight. Plates were washed 3 times with PBS-TW. 100 l of serum diluent was added to wells for serum analysis, and 90[d were added to 5 wells for milk analysis. 1 l of serum sample and 10l of milk sample added to the serum diluent. The mixture was created by gentle tapping the plate. The plates were stored at 40C overnight. The plates were washed 3 times with PBS-TW. 100p of a 1/2500 dilution of Donkey anti-goat IgG-HRP in 0.85% saline added to each well. The plates were incubated at room temperature for 1 hour. The plates 10 were washed 3 times with PBS-TW. 9 parts of Part A and 1 part of Part B of TMBS were mixed in a glass Schott bottle and 100il was added to each well. The plates were incubated at room temperature for 10 minutes. 1 00Qp 1M H 2 SO4 was added to each well and plate read on spectrophotometer at 450nm. A printout of the absorbance results was obtained. The absorbance values of each 15 milk and blood sample collected from all animals were measured. Plots of absorbance values on the y-axis against time (days) on the x-axis were prepared for individual animals and the average absorbance value for each group (comprising two test subjects). Example 15 20 Lipase diffusion in milk agar slide (i) Prepare 1% (1g/100ml) agar (Oxoid Cat No L13, Basingstoke, Hampshire, England) in Phosphate Buffer Saline (pH 7.4). (ii) Add 100p of whole milk (Masters, Perth, Australia) to 5ml 1% agar. 25 (iii) For slide format, 2.5ml of 'milk agar' is poured over the glass and allowed to set for 10 minutes (2% milk in 1% agar). (iv) Five 1.5mm diameter holes in the milk agar gel were prepared with an agar punch and the agar removed by vacuum.

WO 2006/037183 PCT/AU2005/001541 - 33 (v) The agar film was incubated over night with lipase from P. fluorescens (Aldrich, Milwaukee, WI, USA). 5mg/ml of lipase was prepared in 0.85% saline. (vi) The diffusion zone, indicative of lipid degradation of the lipase test was 5 compared to a plate with (a) saline, (b) lipase + antibody negative serum and (c) lipase + anti-lipase positive serum. Results are present in Figure 13. On each milk slide, 5 wells were filled with saline (slide 1), the lipase enzyme (slide 2), lipase with an antibody negative 10 serum (slide 3) and lipase with an anti-lipase antibody positive serum (slide 4). In slide 2, a zone of hydrolysis is visible as the lipase enzyme hydrolyses the lipids in the milk film. The negative control (saline in slide 1) confirms that the enzyme is responsible for the zone of hydrolysis. The hydrolysis activity of the lipase enzyme can be inhibited by an anti-lipase antibody, as evident in slide 4. Slide 3, 15 which contains an antibody negative serum, confirms that it is the antibody and not other components of serum that is inhibiting the enzyme. Example 15 Milk agar plates 20 (i) 1% milk in 1% agar was prepared. (ii) 10mls of the solution was poured into Petri dishes and allowed to set at room temperature. (iii) Six 1.5mm diameter holes were prepared in the agar with a punch, and 25 removed by vacuum. (iv) The wells were filled with 1:1 pre-bleed sera + PBS solution (well 1), 1:1 pre-bled sera + lipase solution (well 2), 2.5mg/mi lipase (well 3), 1:1 anti lipase sera (38 days) + PBS solutions (well 4), 1:1 anti-lipase sera (38 days) + lipase (well 5), and 0.85% PBS (well 6) (see schema on Figure 5 30 for position of each well). Results are present in Figures 14 and 15.

WO 2006/037183 PCT/AU2005/001541 - 34 Figure 14 shows a 1% milk in 1% agar plate with wells containing 1:1 ratio of pre bleed sera + PBS solution (well 1), 1:1 pre-bled sera + lipase solution (well 2), 2.5mg/mi lipase (well 3), 1:1 anti-lipase sera (38 days) + PBS solutions (well 4), 1:1 anti-lipase sera (38 days) + lipase (well 5), and 0.85% PBS (well 6). 5 In we((ll 2 and 3, a zone of lipid hydrolysis is evident as a result of the activity of the lipase enzyme. In well 5, the activity of lipase is inhibited by the addition of serum containing anti-lipase activity. Well 1, which serum does not contain antibodies, shows no hydrolytic activity. This show that there components of the serum does 10 not affect lipids in milk. Similarly, the serum that contains anti-lipase antibodies does not hydrolyse lipids in milk (well 4). Lane 6 is a negative control (containing only PBS) and shows no hydrolysis of lipids. In summary, the addition of lipase hydrolyses lipids that are contained within milk 15 contained in the milk agar plate as evident in wells 2 and 3. There appears to be elements in the serum that enhances the hydrolytic activity, when the diameter of zoning is compared between wells 3 and 2. This is not unexpected, since serum is a protein rich solution that may contain elements that are synergistic with the lipase enzyme. Nevertheless, the hydrolytic activity of the lipase enzyme, 20 including the factors of serum, is completely inhibited by the inclusion of the anti lipase antibody (see well 5). There was no hydrolytic activity produced by serum only (well 1 and 4) and saline (well 6). In Figure 15, the same milk agar plate setup was established to compare the 25 inhibitory activity on the lipase enzyme. X0247 and X0248 contained anti-lipase antibodies from two different sources. X0249, X0250, X0251 and X0252 contains antibodies directed against other proteins. In wells 2 and 3 of each of the six plates, lipid hydrolysis was evident. In well 5 containing the respective antibodies, inhibition was only evident for milk plate X0247 and X0248 that contained the anti 30 lipase antibody. In contrast, the other antibodies did not inhibit tipase activity.

WO 2006/037183 PCT/AU2005/001541 - 35 Example 16 Lipid hydrolysis by lipase assay by pH (i) In McCartney bottles, add 5ml of 0.05M Sodium Carbonate (Ajax-Univar) to 5 1 Oml fresh milk (Harvey Fresh, Harvey, Western Australia). (ii) Incubate mixture at 370C for 5 minutes. (iii) In a separate McCartney, incubate 500pl of 5mg/ml lipase at 400C. (iv) Add the milk/sodium carbonate solution to the lipase. (v) Insert pH probe and record pH at desired 30 second intervals. 10 Figure 16 summarises the results of an experiment which measures the hydrolytic activity of lipase. Briefly, fresh milk was incubated with the lipase enzyme at 370C. The pH of milk was measured before the commencement of the experiment and at 30 second intervals after lipase was added. As lipids in the 15 milk are hydrolysed, the free fatty acids that are liberated reduce the pH of the milk. The change in pH of milk incubated with lipase at 370C was plotted (Figure 16). The reduction of pH followed a hyperbolic pattern. When anti-lipase antibodies were added, the rate of pH change was reduced in a dose-dependant manner. The rate of pH change was less when greater concentrations of the anti 20 lipase antibody were added. Furthermore, the shape of the curve was linear. Example 17 Inhibition of lipid hydrolysis by lipase using an anti-lipase antibody. 25 (i) The lipid hydrolysis assay by pH was used in a comparative study to evaluate the inhibitory properties of anti-lipase antibodies. Specifically, a series of lipid hydrolysis assays were establish with the following additions: a. a pre-bleed serum (ie. antibody negative serum), b. 24041 of anti-lipase positive serum, 30 c. 500pI of anti-lipase positive serum, d. 1000pl of anti-lipase positive serum. (ii) pH was measured at 30 seconds interval and the results were plotted.

WO 2006/037183 PCT/AU2005/001541 -36 Results from examples 16 and 17 are presented in Figures 16, 17 and 18. Further data is presented in Figures 19 and 20. 5 In Figure 17, the data from Figure 16 are plotted with two additional data sets. Milk was incubated with lipase and an antibody negative serum (,). The curve showing pH change was similar to the curve for the control (ie. milk + lipase only). The anti-lipase antibody was titrated to lower concentrations (ie. 1000pl, 5001l and 250V1). The results suggest that antibody concentration is rate-limiting factor. 10 The 2504 1 curve is parabolic an not linear, suggesting that antibodies level are limited and hydrolytic activity of the enzyme is not complete. The experiment was repeated at 100C and 40C. At 100C, the rate of pH change between lipase spike milk that contain antibody and those that do not contain the 15 antibody were similar, indicating that mechanisms other that lipase hydrolysis is at work. At 40C, the rate of change without antibody was greater when compared to the sample containing the anti-lipase antibody. Example 18 Shelf-life assessment by measuring pH as an indicator of lipid hydrolysis. 20 (i) Hydrolysis of lipids as measured by pH change was performed at 1 OC and at 4 0 C. (ii) pH was measured daily from a series of samples containing saline (PBS), 10% pre-bleed serum (antibody negative serum) and 10% anti-lipase 25 positive serum. Results are presented in Figures 21 and 22. Milk was incubated with lipase and eight dilutions of serum containing anti-lipase antibody. A positive control (lipase only with no serum) and a negative serum 30 (saline or PBS only) were also prepared for comparison. The pH of milk was measured prior to start of the experiment and one hour after incubation. At the 1:2 and 1:5 dilutions, the pH change was minimal. As the concentrations of WO 2006/037183 PCT/AU2005/001541 - 37 antibodies are decreased, the pH changes are distinct, suggesting an antibody dose-effect on the lipolysis of milk fat by lipase. In contrast, milk that was incubated with serum containing no antibodies showed 5 the hydrolytic activity of lipase. The change in pH over the incubation period (1 hr) suggests that lipase is hydrolyzing the lipids in the milk. Although the invention has been described with reference to certain preferred embodiments, it will be appreciated that many variations and modifications may be made within the scope of the broad principles of the invention. Hence, it is 10 intended that the preferred embodiments and all of such variations and modifications be included within the scope and spirit of the invention.

Claims (37)

1. A method for improving the half-life of milk comprising the step of: a) contacting milk with an antibody raised against at least one of the following: i) a molecule required for survival by at least a micro-organism that is 5 responsible for reducing the half-life of milk; ii) a molecule required for growth by at least a micro-organism that is responsible for reducing the half-life of milk; iii) a molecule required for survival by at least a micro-organism that aids other micro-organisms to reduce the half-life of milk; 10 iv) a molecule required for growth by at least a micro-organism that aids other micro-organisms to reduce the half-life of milk.

2. The method of claim 1 wherein the method prolongs the shelf-life of the milk.

3. The method of claim 1 or 2 wherein the antibody, when contacted with the milk, forms an antibody-antigen interaction with the molecule which depletes, 15 removes or prevents the molecule from being a nutrient source for the micro organism or prevents the activity of the molecule.

4. The method of claim 3 wherein the antibody is an antibody generated against lipoprotein lipase from Pseudomonas fluorescens.

5. The method of any one of claims 1 to 4 wherein the antibody molecules are 20 chosen from the list comprising: intact immunoglobulin molecules, substantially intact immunoglobulin molecules and portions of an immunoglobulin molecule that contain the paratope. WO 2006/037183 PCT/AU2005/001541 -39

6. The method of claim 5 wherein the portion of an immunoglobulin molecule that contain the paratope is selected from the list comprising: Fab, Fab', F(ab') 2 and F(v) portions.

7. A method for improving the half-life of milk comprising the step of: 5 a) inducing the production of at least an antibody in the mammary gland of an animal, which antibody is raised against at least one of the following: i) a molecule required for survival by at least a micro-organism that is responsible for reducing the half-life of milk; ii) a molecule required for growth by at least a micro-organism that is 10 responsible for reducing the half-life of milk; iii) a molecule required for survival by at least a micro-organism that aids other micro-organisms to reduce the half-life of milk; iv) a molecule required for growth by at least a micro-organism that aids other micro-organisms to reduce the half-life of milk. 15

8. A method according to claim 7 wherein the method prolongs the shelf-life of the milk.

9. A method for the induction of antibody production in milk for improving the half life of milk comprising the step of: a) implanting at least one antigen releasing device adjacent to or within at 20 least one supramammary lymph node, wherein in use the antigen releasing device releases an antigen into the tissue area around the supramammary lymph node which stimulates antibody secretion into a mammary gland. WO 2006/037183 PCT/AU2005/001541 - 40

10.The method of claim 9 wherein the shelf-life of the milk is prolonged.

11.The method of claim 9 wherein the implant is located in sufficient proximity to the supramammary gland such that the release of antigen from the antigen releasing device induces the production of antibodies in milk over the life of the 5 antigen releasing device.

12.The method of claim 11 wherein the antigen releasing device is implanted at a distance of up to 100 mm from at least one supramammary lymph node.

13. The method of claim 12 wherein the antigen releasing device is implanted at a distance of between about 1 mm and 100 mm from at least one 10 supramammary lymph node.

14. The method of claim 13 wherein the antigen releasing device is implanted at a distance of between about 50 mm and 100 mm from at least one supramammary lymph node.

15.A method for inducing the sustained release of antibodies in milk to prolong 15 the half-life of the milk comprising the steps of: a) administering a primer composition; and b) implanting at least one antigen releasing device adjacent to, within close proximity of or within at least one supramammary lymph node, wherein in use the antigen releasing device releases an antigen into the tissue 20 area around the supramammary lymph node which stimulates antibody secretion into a mammary gland.

16.A method for inducing the sustained release of antibodies in milk to prolong the half-life of the milk comprising the step of: WO 2006/037183 PCT/AU2005/001541 - 41 a) implanting at least one antigen releasing device adjacent to, within close proximity of or within at least one supramammary lymph node, and b) administering a booster composition comprising antigen to a mammal after the antigen releasing device has been implanted 5 wherein in use the antigen releasing device releases an antigen into the tissue area around the supramammary lymph node which stimulates antibody secretion into a mammary gland.

17.A method for inducing the sustained release of antibodies in milk to prolong the half-life of the milk comprising the step of: 10 a) administering a primer composition; b) implanting at least one antigen releasing device adjacent to, within close proximity of or within at least one supramammary lymph node; and c) administering a booster composition comprising antigen to a mammal after the antigen releasing device has been implanted 15 wherein in use the antigen releasing device releases an antigen into the tissue area around the supramammary lymph node which stimulates antibody secretion into a mammary gland.

18.The method of claim 15 or 17 wherein the primer is administered by an administration route selected from: intramammary, intraperitoneal, 20 intramuscular or intranasal.

19.The method of claim 15 or 17 wherein administration of a primer takes place before implanting the antigen releasing device.

20.The method of claim 15 or 17 wherein administration of a primer takes place during implantation of the antigen releasing device. WO 2006/037183 PCT/AU2005/001541 - 42

21.The method of claim 15 or 17 where the primer composition is delivered to a mucosal surface.

22.The method of claim 15 or 17 wherein the primer composition is administered in a single administration. 5

23.The method of claim 15 or 17 wherein the primer composition is administered in a number of administrations at intervals over a period of days or weeks.

24.The method of claim 16 or 17 wherein the booster is administered by an administration route selected from: intramammary, intraperitoneal, intramuscular and/or intranasal. 10

25.A method according to claim 16 or 17 wherein the booster composition is delivered to a mucosal surface.

26. The method of claim 16 or 17 wherein the booster composition is administered in a single administration.

27.The method of claim 16 or 17 wherein the booster composition is administered 15 in a number of administrations at intervals over a period of days or weeks.

28.The method of any one of claims 15 to 27 wherein the antigen administered is the same for each step of the method.

29.The method of any one of claims 15 to 28 wherein the antigen releasing device, the priming composition and the booster composition further comprise 20 an adjuvant.

30.A method according to any one of claims 1 to 29 further comprising a preselection step prior to administration of the antigen releasing device wherein animals showing the best antibody titre responses are used in the methods of any one of claims 1 to 29. WO 2006/037183 PCT/AU2005/001541 - 43

31.A method for the production of milk with an improved half-life containing antibodies, comprising the steps of: a) inducing antibodies using the method of any one of claims 15-30; and b) collecting the antibody containing milk from the mammal 5 wherein the antibodies prolong the half-life of the milk.

32.The method of claim 31 wherein the antibodies prolong the shelf-life of the milk.

33.A milk product with prolonged half-life, said milk product being prepared from milk generated according to the method of any one.of claims 1-32 and wherein 10 milk produced by the method is processed into the milk product.

34.A milk product with prolonged shelf-life, said milk product being prepared from milk generated according to the method of any one of claims 1-32 and wherein milk produced by the method is processed into the milk product.

35.A milk product with prolonged half-life, said product being a milk product or 15 derivative whose half-life is prolonged by the addition of an antibody raised against at least one of the following: i) a molecule required for survival by at least a micro-organism that is responsible for reducing the half-life of milk; ii) a molecule required for growth by at least a micro-organism that is 20 responsible for reducing the half-life of milk; iii) a molecule required for survival by at least a micro-organism that aids other micro-organisms to reduce the half-life of milk; WO 2006/037183 PCT/AU2005/001541 - 44 iv) a molecule required for growth by at least a micro-organism that aids other micro-organisms to reduce the half-life of milk.

36.A milk product with prolonged shelf-life, said product being a milk product or derivative whose shelf-life is prolonged by the addition of an antibody raised 5 against at least one of the following: i) a molecule required for survival by at least a micro-organism that is responsible for reducing the shelf-life of milk; ii) a molecule required for growth by at least a micro-organism that is responsible for reducing the shelf-life of milk; 10 iii) a molecule required for survival by at least a micro-organism that aids other micro-organisms to reduce the shelf-life of milk; iv) a molecule required for growth by at least a micro-organism that aids other micro-organisms to reduce the shelf-life of milk.

37.The milk product of any one of claims 33-36 wherein milk containing 15 antibodies is subjected to heat treatment, ultra violet radiation, concentration, supplementation with food additives, drying into a concentrate or milk powder to form the milk product.